HomepageCGEN • NASDAQ
add
Compugen Ltd
$Â 1,45
Na sluitingstijd:(2,07%)+0,030
$Â 1,48
Gesloten: 16 apr, 16:25:39 GMT-4 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 1,38
Dag-range
$Â 1,38 - $Â 1,48
Jaar-range
$Â 1,13 - $Â 2,66
Beurswaarde
129,83Â mln. USD
Gem. volume
285,39K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,47Â mln. | -95,60% |
Bedrijfskosten | 8,28Â mln. | -38,54% |
Netto inkomsten | -6,12Â mln. | -162,98% |
Netto winstmarge | -415,84 | -1.532,45% |
Winst per aandeel | -0,07 | -163,64% |
EBITDA | -7,36Â mln. | -140,66% |
Effectief belastingtarief | -0,07% | — |
Balans
Totale activa
Totale passiva
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 103,26Â mln. | 103,72% |
Totale activa | 115,00Â mln. | -5,22% |
Totale passiva | 60,08Â mln. | 7,72% |
Totaal aandelenvermogen | 54,91 mln. | — |
Uitstaande aandelen | 93,51 mln. | — |
Koers-boekwaardeverhouding | 2,26 | — |
Rendement op activa | -15,69% | — |
Rendement op kapitaal | -30,85% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -6,12Â mln. | -162,98% |
Operationele kasstroom | — | — |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | — | — |
Vrije kasstroom | — | — |
Over
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Opgericht
10 feb 1993
Website
Werknemers
74